FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan ($19.8 million). Looking up: The…
FAST NEWS: Antengene Acquires Full Interest in Anti-Tumor Cancer Drug
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving…
FAST NEWS: Antengene Appoints New Chief Medical Officer
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday Kevin Patrick Lynch has resigned as an executive director and chief medical officer (CMO) to retire, but will remain…
FAST NEWS: Antengene Invests $36 Million in Drug Discovery Center
The latest: Biopharma company Antengene Corp. Ltd. (6996.HK) announced Monday it has entered into an agreement with a contractor to build a drug discovery and manufacturing center for antibody biologics in…
RELATED ARTICLES
-
FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug
6996.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
